| Identification | Back Directory | [Name]
BAY-1217389 | [CAS]
1554458-53-5 | [Synonyms]
CS-2361
BAY-1217389
BAY-1217389 BAY 1217389， BAY 1217389）
Benzamide, N-cyclopropyl-4-[6-(2,3-difluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl]-2-methyl- | [Molecular Formula]
C27H24F5N5O3 | [MDL Number]
MFCD30502614 | [MOL File]
1554458-53-5.mol | [Molecular Weight]
561.5 |
| Chemical Properties | Back Directory | [density ]
1.47±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 25 mg/ml; DMF:PBS (pH 7.2)(1:3): 0.25 mg/ml; DMSO: 15 mg/ml | [form ]
A crystalline solid | [pka]
14.58±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
N-Cyclopropyl-4-[6-(2,3-difluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide inhibits monopolar spindle 1, which is a serine/threonine/tyrosine kinase involved in cell division. It is also a potential antitumor agent. | [in vivo]
BAY 1217389 achieves moderate efficacy in monotherapy in tumor xenograft studies. However, in line with its unique mode of action, when combines with paclitaxel, low doses of Mps1 inhibitor reduces paclitaxel-induced mitotic arrest in line with weakening of SAC activity. As a result, combination therapy strongly improves efficacy over paclitaxel or Mps1 inhibitor monotreatment at the respective MTDs in a broad range of xenograft models including those showing acquired or intrinsic paclitaxel-resistance. BAY 1217389 shows good tolerability without adding toxicity to paclitaxel monotherapy[1]. | [IC 50]
Mps1: 0.63 nM (IC50) | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|